Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations

British Journal of Cancer

Volumn 110, Issue 4, 2014, Pages 1045-1052

  Secq, V ^a,b,c   Villeret, J ^a   Fina, F ^d   Carmassi, M ^a   Carcopino, X ^a,b   Garcia, S ^a,b,c   Metellus, I ^d   Boubli, L ^a,b   Iovanna, J ^c   Charpin, C ^a,b,c  

^a HÔPITAL NORD   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c INSERM   (France)

^d University of the Mediterranean Aix Marseille II   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CYCLE PROTEINS; DNA, CIRCULAR; FEMALE; GENE AMPLIFICATION; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SERINE ENDOPEPTIDASES; TRANSLOCATION, GENETIC; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84894358061     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.794     Document Type: Article

References (39)

1. Bhargava R, Gerald WL, Li AR, Pan Q, Lal P, Ladanyi M, Chen B (2005) EGFR gene amplification in breast cancer: Correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-Activating mutations. Mod Pathol 18: 1027-1033.
2. Brachmann SM, Hofmann I, Schnell C, Fritsch C, Wee S, Lane H, Wang S, Garcia-Echeverria C, Maira SM (2009) Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. PNAS 106: 22299-22304.
3. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, Mueller R, Nolan T, Pfaffl MW, Shipley GL (2009) The MIQE guidelines: Minimum information for publication of quantitative real-Time PCR experiments. Clin Chem 55: 611-622.
4. Carey L, Winer E, Viale G, Cameron D, Gianni L (2010) Triple-negative breast cancer: Disease entity or title of convenience? Nat Rev Clin Oncol 7: 683-692.
5. Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, Ma CX, Liu MC, Storniolo AM, Rimawi MF, Forero-Torres A, Wolff AC, Hobday TJ, Ivanova A, Chiu WK, Ferraro M, Burows E, Bernard PS, Hoadley KA, Perou CM, Winer EP (2012) TBCRC 001: Randomized phase ii study of cetuximab in combination with carboplatin in stage iv triple-negative breast cancer. J Clin Oncol 30: 2615-2623.
6. Charpin C, Giusiano S, Secq V, Carpentier S, Andrac L, Lavaut MN, Allasia C, Bonnier P, Garcia S (2009a) Quantitative immunocytochemical profile to predict early outcome of disease in triple-negative breast carcinomas. Int J Oncol 34: 983-993.
7. Charpin C, Secq V, Giusiano S, Carpentier S, Andrac L, Lavaut MN, Allasia C, Bonnier P, Garcia S (2009b) A signature predictive of disease outcome in breast carcinomas, identified by quantitative immunocytochemical assays. Int J Cancer 124: 2124-2134.
8. Corkery B, Crown J, Clynes M, O'Donovan N (2009) Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. Ann Oncol 20: 862-867.
9. Da Silva L, Clarke C, Lakhani SR (2007) Demystifying basal-like breast carcinomas. J Clin Path 60: 1328-1332.
10. De Ruijter TC, Veeck J, De Hoon J, Van Engeland M, Tjan-Heijnen VC (2011) Characteristics of triple-negative breast cancer. J Cancer Res Clin Oncol 137: 183-192.
11. El Guerrab A, Zegrour R, Nemlin CC, Vigier F, Cayre A, Penault-Llorca F, Rossignol F, Bignon YJ (2011) Differential impact of EGFR-Targeted therapies on hypoxia responses: Implications for treatment sensitivity in triple-negative metastatic breast cancer. PLoS One 6: E25080.
12. Generali D, Leek R, Fox SB, Moore JW, Taylor C, Chambers P, Harris AL (2007) EGFR mutations in exons 18-21 in sporadic breast cancer. Ann Oncol 18: 203-205.
13. Gibaud A, Vogt N, Hadj-Hamou NS, Meyniel JP, Hupe P, Debatisse M, Malfoy B (2010) Extrachromosomal amplification mechanisms in a glioma with amplified sequences from multiple chromosome loci. Hum Mol Gene 19: 1276-1285.
14. Gumuskaya B, Alper M, Hucumenoglu S, Altundag K, Uner A, Guler G (2010) EGFR expression and gene copy number in triple-negative breast carcinoma. Canc Genet Cytogenet 203: 222-229.
15. Guzel O, Guner El (2009) ISO 15189 accreditation; Requirements for quality and competence of medical laboratories, experience of a laboratory I. Clin Biochem 42: 274-278.
16. Jacot W, Lopez-Crapez E, Thezenas S, Senal R, Fina F, Bibeau F, Romieu G, Lamy P-J (2011) Lack of EGFR-Activating mutations in European patients with triple-negative breast cancer could emphasise geographic and ethnic variations in breast cancer mutation profiles. Breast Cancer Res 13: R133.
17. Lamy PJ, Fina F, Bascoul-Mollevi C, Laberenne AC, Martin PM, Ouafik LH, Jacot W (2011) Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-Amplified breast cancers. Breast Cancer Research 13: R15.
18. Lamy PJ, Nanni I, Fina F, Bibeau F, Romain S, Dussert C, Penault-Llorca F, Grenier J, Ouafik LH, Martin PM (2006) Reliability and discriminant validity of HER2 gene quantification and chromosome 17 aneusomy analysis by real-Time PCR in primary breast cancer. Int J Biol Markers 21: 20-29.
19. Lin E, Li L, Guan Y, Soriano R, Rivers CS, Mohan S, Pandita A, Tang J, Modrusan Z (2009) Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. Mol Cancer Res 7: 1466-1476.
20. Lynch TJ, BellDW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139.
21. Macaskill EJ, Bartlett JM, Sabine VS, Faratian D, Renshaw L, White S, Campbell FM, Young O, Williams L, Thomas JS, Barber MD, Dixon JM (2011) The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: Results of a pre-operative study. Breast Cancer Res Treat 128: 725-734.
22. Martin V, Botta F, Zanellato E, Molinari F, Crippa S, Mazzucchelli L, Frattini M (2012) Molecular characterization of EGFR and EGFR-downstream pathways in triple negative breast carcinomas with basal like features. Histol Histopathol 27: 785-792.
23. Mondello C, Smirnova A, Giulotto E (2010) Gene amplification, radiation sensitivity and DNA double-strand breaks. Mutation Research 704: 29-37.
24. Nakajima H, Ishikawa Y, Furuya M, Sano T, Ohno Y, Horiguchi J, Oyama T (2012) Protein expression, gene amplification, and mutational analysis of EGFR in triple-negative breast cancer. Breast Cancer 21(1): 66-74.
25. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, Van De Rijn M, Perou CM (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10: 5367-5374.
26. O'Shaughnessy J, Osborne C, Pippen JE, Yoffe M, Patt D, Rocha C, Koo IC, Sherman BM, Bradley C (2011) Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 364: 205-214.
27. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M (2004) EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304: 1497-1500.
28. Reis-Filho JS, Pinheiro C, Lambros MB, Milanezi F, Carvalho S, Savage K, Simpson PT, Jones C, Swift S, Mackay A, Reis RM, Hornick JL, Pereira EM, Baltazar F, Fletcher CD, Ashworth A, Lakhani SR, Schmitt FC (2006) EGFR amplification and lack of activating mutations in metaplastic breast carcinomas. J Pathol 209: 445-453.
29. Reis-Filho JS, Tutt AN (2008) Triple negative tumours: A critical review. Histopathol 52: 108-118.
30. Rios J, Puhalla S (2011) PARP inhibitors in breast cancer: BRCA and beyond. Oncology 25: 1014-1025.
31. Ryden L, Jirstrom K, Haglund M, Stal O, Ferno M (2010) Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-Term follow-up. Breast Cancer Res Treat 120: 491-498.
32. Sanger F, Air GM, Barrell BG, Brown NL, Coulson AR, Fiddes CA, Hutchison CA, Slocombe PM, Smith M (1977) Nucleotide sequence of bacteriophage phi X174 DNA. Nature 265: 687-695.
33. Shah SP, Roth A, Goya R, Olumi A, Ha G, Zhao Y, Turashvili G, Ding J, Tse K, Haffari G, Bashashati A, Prentice LM, Khattra J, Burleigh A, Yap D, Bernard V, McPherson A, Shumansky K, Grisan A, Giuliany R, Heravi-Moussavi A, Rosner J, Lai D, Birol I, Varhol R, Tam A, Dhalla N, Zeng T, Ma K, Chan SK, Griffith M, Moradian A, Grace Cheng SW, Morin GB, Watson P, Gelmon K, Chia S, Chin SF, Curtis C, Rueda OM, Pharoah PD, Damaraju S, Mackey J, Hoon K, Harkins T, Tadigotla V, Sigaroudinia M, Gascard P, Tlsty T, Costello JF, Meyer IM, Eaves CJ, Wasserman WW, Jones S, Huntsman D, Hirst M, Caldas C, Marra MA, Aparicio S (2012) The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486: 395-399.
34. Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A (2009) Biomarkers predicting clinical outcome of epidermal growth factor receptor-Targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 101: 1308-1324.
35. Teng YH, Tan WJ, Thike AA, Cheok PY, Tse GM, Wong NS, Yip GW, Bay BH, Tan PH (2011) Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: Possible implications for targeted therapy. Breast Cancer Res 13: R35.
36. Thike AA, Cheok PY, Jara-Lazaro AR, Tan B, Tan P, Tan PH (2010) Triple-negative breast cancer: Clinicopathological characteristics and relationship with basal-like breast cancer. Mod Pathol 23: 123-133.
37. Vogt N, Gibaud A, Almeida A, Ourliac-Garnier I, Debatisse M, Malfoy B (2010) Relationships linking amplification level to gene over-expression in gliomas. PLoS One 5: E14249.
38. Vogt N, Lefevre SH, Apiou F, Dutrillaux AM, Cor A, Leuraud P, Poupon MF, Dutrillaux B, Debatisse M, Malfoy B (2004) Molecular structure of doubleminute chromosomes bearing amplified copies of the epidermal growth factor receptor gene in gliomas. PNAS 101: 11368-11373.
39. Yanikkaya-Demirel G (2009) ISO 15189 accreditation: Requirements for quality and competence of medical laboratories, experience of a laboratory II. Clin Biochem 42: 279-283.